Daniel Alonso-Alconada, PhD

Research Associate, Neuroscientist
Department of Neonatology
Institute for Womens Health
University College London
Gower Street, London WC1E 6BT, UK

 

Biography

After obtaining his BSc degree in 2006 and a Master degree on Cell and Developmental Biology in 2008, Dr. Alonso-Alconada completed his PhD in 2010 at the University of the Basque Country in Spain, which was focused on the evaluation of the neuro protective effect of cannabinoids to reduce hypoxic-ischemic brain injury and awarded with the Outstanding PhD Thesis Award and the mention of Doctor Europeus due to my international stay at the Università degli studi di Urbino Carlo Bo, Italy. Afterwards, he obtained a postdoctoral position and a Lecturer position later on in Cell Biology and Human Histology, while continued working in the field of neonatal brain injury. Since Jan 2014, he was working as a Research Associate in the Preclinical Neonatal Neuroprotection and Neuroscience group at University College London and also as a Visiting Research Associate at King’s College London. His actual interest is to identify, develop and optimize new and more efficient therapeutic strategies against neonatal encephalopathy, including therapeutic hypothermia, melatonin and cannabinoids.

Research Interest

His research interests include: Neuroprotection, Newborn brain injury, Neonatal encephalopathy, Perinatal hypoxia-ischemia, Brain pathology, Therapeutic interventions.

Scientific Activities

GRANTS AND PRIZES

• (2014-2017) Postdoctoral Fellowship. “Optimizing treatment timing and dose of melatonin neuroprotection of the newborn: a preclinical piglet study”, funded by the Basque Government.
• (2014) 3rd Prize Best Oral Presentation. D. Alonso Alconada. The Optimum Therapeutic Hypothermia Temperature is 33.5ºC in a Piglet Perinatal Asphyxia Model. 9th Institute for Womens Health Annual Meeting Programm, UCL, London, UK.
• (2012) Outstanding PhD Thesis Award “Study of the perinatal hypoxicischemic brain injury. Therapeutic effect of the cannabinoid agonist WIN 55,212-2”, University of the Basque Country.
• (2009) PhD Parallel Grant, funded by the Basque Government.
• (2008) PhD Parallel Grant, funded by the Basque Government.
• (2009) Scientific Stays Program, International Visiting Fellowsip. “Role of autophagy in neonatal hypoxia-ischemia inducing neurodegenration”. Università degli studi di Urbino Carlo Bo, Italy, funded by the Basque Government. 3,000€.
• (2010) Best Oral Presentation Award. 11th Meeting of the Spanish Society for Cannabinoid Research (SEIC). Pontevedra, Spain, 2010.
• (2008-2010) Predoctoral Fellowship. “Neuroprotective effect of the cannabinis system in the experimental hypoxic-ischemic encephalopath”, funded by the Basque Government.
• (2007-2008) Starting Fellow “Role of the adhesion molecules after neonatal brain injury” funded by the Gangoiti Foundation.

PROFESSIONAL EXPERIENCE

• (2014 – Present) Research Associate, Department of Neonatology, Institute for Women’s Health, University College London, UK
• (2014-Present) Visiting Research Associate, Division of Imaging Sciences and Biomedical Engineering, Faculty of Life Sciences and Medicine, King’s College London, UK
• (2012-2014) Lecturer, Human Histology, School of Medicine, University of the Basque Country, Spain
• (2012-2013) Lecturer, Cell Biology, School of Medicine, University of the Basque Country, Spain
• (2010-Present) Lecturer, Biomedical Instrumentation, International Master in Biomedical Engineering, University of the Basque Country, Spain
• (2012-Present) Lecturer, Introduction to Biomedicine, International Master in Biomedical Engineering, University of the Basque Country, Spain
• (2011-Present) Lecturer, Advances in Neurotransmission and Neuromodulation, Master in Biomedical Research, University of the Basque Country, Spain
• (2010-2012) Postdoctoral Researcher, University of the Basque Country, Spain. Therapeutics against perinatal hypoxia-ischemia
• (2008-2010) PhD Researcher: “Study of the perinatal hypoxic-ischemic brain injury. Therapeutic effect of the cannabinoid agonist WIN 55,212-2”, University of the Basque Country, Spain

Publications

RESEARCH ARTICLES

1. Alonso-Alconada D, Broad KD, Bainbridge A, et al. Brain Cell Death Is Reduced With Cooling by 3.5°C to 5°C but Increased With Cooling by 8.5°C in a Piglet Asphyxia Model. Stroke. 2014; STROKEAHA.114.007330. doi: 10.1161/STROKEAHA.114.007330
2. Alonso-Alconada D, Alvarez A, Arteaga O, Martínez-Ibargüen A, Hilario E. Neuroprotective Effect of Melatonin: A Novel Therapy against Perinatal Hypoxia- Ischemia. Int J Mol Sci. 2013; 14(5): 9379-9395. doi: 10.3390/ijms14059379.
3. Carloni S, Alonso-Alconada D, Girelli S, et al. Pretreatment with the monoacylglycerol lipase inhibitor URB602 protects from the long-term consequences of neonatal hypoxicischemic brain injury in rats. Pediatr Res. 2012; 72(4): 400-406. doi: 10.1038/pr.2012.91
4. Goñi-de-Cerio F, Alvarez A, Alvarez FJ, Alonso-Alconada D, Hilario E. Magnesium sulfate decreases the initial brain damage alterations produced after asphyxia in fetal lambs. J Neurosci Res. 2012; 90(10): 1932-1940. doi: 10.1002/jnr.23091
5. Alonso-Alconada D, Alvarez A, Lacalle J, Hilario E. Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol Histopathol. 2012; 27(6): 771-783.
6. Alonso-Alconada D, Hilario E, Alvarez FJ, Alvarez A. Apoptotic Cell Death Correlates with ROS Over-Production and Early Cytokine Expression after Hypoxia- Ischemia in Fetal Lambs. Reprod Sci. 2012; 19(7): 754-763. doi: 10.1177/1933719111432868
7. Alonso-Alconada D, Alvarez A, Alvarez-Granda L, Hilario E. Therapeutic potential of the endocannabinoid system in perinatal asphyxia. Rev Neurol. 2011; 53(12): 758-764.
8. Alonso-Alconada D, Alvarez A, Alvarez FJ, Martinez-Orgado J, Hilario E. The cannabinoid WIN 55,212-2 mitigates apoptosis and mitochondrial dysfunction after hypoxia-ischemia. Neurochem Res. 2012; 37(1): 161-170. doi: 10.1007/s11064-011-0594-z
9. Alonso-Alconada D, Alvarez A, Hilario E. Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury. Neurosci Bull. 2011; 27(4): 275-285. doi: 10.1007/s12264-011-1008-6
10. Alonso-Alconada D, Alvarez FJ, Alvarez A, et al. The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic-ischemic injury in fetal lambs. Brain Res. 2010; 1362: 150-159. doi: 10.1016/j.brainres.2010.09.050
11. Goñi-de-Cerio F, Alvarez A, Alvarez FJ, et al. MgSO4 treatment preserves the ischemiainduced reduction in S-100 protein without modification of the expression of endothelial tight junction molecules. Histol Histopathol. 2009; 24: 1129-1138.